Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.

ABSTRACT:

Background

MDV3100 is an androgen-receptor antagonist that blocks androgens from binding to the androgen receptor and prevents nuclear translocation and co-activator recruitment of the ligand-receptor complex. It also induces tumour cell apoptosis, and has no agonist activity. Because growth of castration-resistant prostate cancer is dependent on continued androgen-receptor signalling, we assessed the antitumour activity and safety of MDV3100 in men with this disease.

Methods

This phase 1-2 study was undertaken in five US centres in 140 patients. Patients with progressive, metastatic, castration-resistant prostate cancer were enrolled in dose-escalation cohorts of three to six patients and given an oral daily starting dose of MDV3100 30 mg. The final daily doses studied were

SUBMITTER: Scher HI 

PROVIDER: S-EPMC2948179 | biostudies-literature | 2010 Apr

REPOSITORIES: biostudies-literature